Niagen Bioscience, Inc.NAGEEarnings & Financial Report
Niagen Bioscience, formerly ChromaDex, is a bioscience сompany based in Los Angeles, California founded in 1999. The company operates in multiple sectors including reference standards, dietary supplements, and ingredient technology. Niagen Bioscience is publicly traded on the NASDAQ.
NAGE Q4 FY2025 Key Financial Metrics
Revenue
$33.8M
Gross Profit
$21.7M
Operating Profit
$4.1M
Net Profit
$4.1M
Gross Margin
64.1%
Operating Margin
12.1%
Net Margin
12.2%
YoY Growth
16.2%
EPS
$0.05
Niagen Bioscience, Inc. Q4 FY2025 Financial Summary
Niagen Bioscience, Inc. reported revenue of $33.8M (up 16.2% YoY) for Q4 FY2025, with a net profit of $4.1M (down 42.4% YoY) (12.2% margin). Cost of goods sold was $12.1M, operating expenses totaled $17.6M.
Key Financial Metrics
| Total Revenue | $33.8M |
|---|---|
| Net Profit | $4.1M |
| Gross Margin | 64.1% |
| Operating Margin | 12.1% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Niagen Bioscience, Inc. Q4 FY2025 revenue of $33.8M breaks down across 3 segments, led by TRUNIAGEN Consumer Product at $27.5M (81.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| TRUNIAGEN Consumer Product | $27.5M | 81.1% |
| Ingredients Segment | $5.7M | 16.8% |
| Other | $694.0K | 2.1% |
Niagen Bioscience, Inc. Revenue by Segment — Quarterly Trend
Niagen Bioscience, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as TRUNIAGEN Consumer Product and Ingredients Segment) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| TRUNIAGEN Consumer Product | $27.5M | $26.0M | $22.7M | $21.5M |
| Ingredients Segment | $5.7M | $7.2M | — | $8.2M |
| Other | $694.0K | — | $1.0M | — |
Niagen Bioscience, Inc. Annual Revenue by Year
Niagen Bioscience, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $129.4M).
Niagen Bioscience, Inc. Quarterly Revenue & Net Profit History
Niagen Bioscience, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $33.8M | +16.2% | $4.1M | 12.2% |
| Q3 FY2025 | $34.0M | +32.9% | $4.6M | 13.5% |
| Q2 FY2025 | $31.1M | +36.8% | $3.6M | 11.6% |
| Q1 FY2025 | $30.5M | +37.6% | $5.1M | 16.6% |
| Q4 FY2024 | $29.1M | +37.4% | $7.2M | 24.6% |
| Q3 FY2024 | $25.6M | +31.2% | $1.9M | 7.3% |
| Q2 FY2024 | $22.7M | +11.9% | $-15.0K | -0.1% |
| Q1 FY2024 | $22.2M | -1.8% | $-492.0K | -2.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.2M | $22.7M | $25.6M | $29.1M | $30.5M | $31.1M | $34.0M | $33.8M |
| YoY Growth | -1.8% | 11.9% | 31.2% | 37.4% | 37.6% | 36.8% | 32.9% | 16.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $54.1M | $54.0M | $56.5M | $68.3M | $81.3M | $91.5M | $98.1M | $106.4M |
| Liabilities | $25.1M | $23.3M | $22.2M | $22.2M | $26.0M | $27.3M | $27.5M | $29.9M |
| Equity | $29.0M | $30.7M | $34.4M | $46.1M | $55.3M | $64.2M | $70.7M | $76.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $295000 | $-264000 | $3.5M | $8.6M | $7.9M | $1.3M | $3.7M | $679000 |